STOCK TITAN

InfuSystem (INFU) files Form 144 to sell 5,752 shares on 08/22/2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

InfuSystem Holdings, Inc. (INFU) filed a Form 144 notifying an intended open-market sale of 5,752 common shares through Charles Schwab with an aggregate market value of $56,455. The filing states the shares were originally acquired on 08/01/2017 via open-market purchase and payment in cash. The proposed approximate sale date is 08/22/2025, and the filing reports 20,425,964 shares outstanding for the issuer. No securities of the issuer were reported sold by the same person in the past three months. The filer affirms they are not aware of any undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine Form 144 disclosing an intended open-market sale of a small block of shares acquired in 2017; appears non-material.

The filing documents a proposed sale of 5,752 common shares valued at $56,455, executed through Charles Schwab and originating from an open-market purchase on 08/01/2017. Given the reported 20,425,964 shares outstanding, this block represents a de minimis portion of the float. The filer also certifies absence of undisclosed material adverse information. For investors, this reads as a routine disclosure of a secondary sale rather than a company-specific event that would materially affect valuation.

TL;DR: Standard Rule 144 notification for compliance; no indication of coordinated insider signal or material disclosure.

The Form 144 provides required compliance details: broker, acquisition date, payment method, and planned sale date. The acquisition was paid in cash and there are no reported sales in the prior three months by the same person, reducing signs of accelerated disposal. The filer’s attestation regarding material information aligns with required certifications. From a governance perspective, this is a routine transparency filing rather than evidence of emergent corporate issues.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does INFU's Form 144 disclose?

The filing discloses an intended open-market sale of 5,752 common shares valued at $56,455, to occur approximately on 08/22/2025, via Charles Schwab.

When were the shares being sold originally acquired?

The shares were acquired on 08/01/2017 in an open-market purchase with payment in cash.

How large is the proposed sale relative to INFU's outstanding shares?

The filing reports 20,425,964 shares outstanding; the 5,752-share block represents a very small fraction of total outstanding shares.

Did the filer report any other sales in the past three months?

No. The section for securities sold during the past three months states Nothing to Report.

Which broker is handling the proposed sale?

The broker listed is Charles Schwab Corp., 3000 Schwab Way, Westlake, TX.
Infusystem Hld

NYSE:INFU

View INFU Stock Overview

INFU Rankings

INFU Latest News

INFU Latest SEC Filings

INFU Stock Data

194.07M
18.78M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ROCHESTER HILLS